



Reactivation of Epigenetically Silenced Genes by DNA Methyltransferase Inhibitors: Basic Concepts and Clinical Applications

Cora Mund, Bodo Brueckner & Frank Lyko

To cite this article: Cora Mund, Bodo Brueckner & Frank Lyko (2006) Reactivation of Epigenetically Silenced Genes by DNA Methyltransferase Inhibitors: Basic Concepts and Clinical Applications, Epigenetics, 1:1, 8-14, DOI: [10.4161/epi.1.1.2375](https://doi.org/10.4161/epi.1.1.2375)

To link to this article: <https://doi.org/10.4161/epi.1.1.2375>



Published online: 10 Mar 2006.



Submit your article to this journal 



Article views: 600



View related articles 



Citing articles: 55 View citing articles 

CELGENE 2022
APOTEX v. CELGENE
IPR2023-00512

Review

Reactivation of Epigenetically Silenced Genes by DNA Methyltransferase Inhibitors

Basic Concepts and Clinical Applications

Cora Mund

Bodo Brueckner

Frank Lyko*

Division of Epigenetics; Deutsches Krebsforschungszentrum; Im Neuenheimer Feld 580; Heidelberg, Germany

*Correspondence to: Frank Lyko, Ph.D.; Deutsches Krebsforschungszentrum; Im Neuenheimer Feld 580; 69120 Heidelberg, Germany; Tel.: +49.6221.423800; Fax: +49.6221.423802; Email: f.lyko@dkfz.de

Received 11/04/05; Accepted 11/29/05

Previously published as an *Epigenetics* E-publication:
<http://www.landesbioscience.com/journals/epigenetics/abstract.php?id=2375>

KEY WORDS

DNA methylation, DNA methyltransferase inhibitors, epigenetic therapy

ABSTRACT

Hypermethylation of tumor suppressor genes is one of the most consistent hallmarks of human cancers. This epigenetic alteration has been associated with gene silencing and thus represents an important pathway for generating loss-of-function mutations. In this review, we survey the available literature on systematic, genome-wide approaches aimed at the identification of epigenetically silenced loci. These studies uncovered a variety of diverse genes, but a common signature for epigenetic reactivation has not been identified. Nevertheless, DNA methyltransferase inhibitors have shown significant clinical benefits, mostly in the therapy of leukemias. Recent analyses revealed substantial drug-induced methylation changes that can now be used as endpoints for the further refinement of clinical treatment schedules. Further optimization of epigenetic cancer therapies should be feasible through the use of novel DNA methyltransferase inhibitors with improved specificity. Rational design of epigenetic inhibitors might provide the foundation for a broader use of these drugs in the treatment of cancer.

Epigenetic mechanisms play a fundamental role in the interpretation of genetic information.¹ Depending on its particular epigenetic modification pattern, a gene can be expressed or silenced. Epigenetic modifications thus represent an integral mechanism for the control of complex gene expression patterns. One prominent example for an epigenetic control mechanism is the covalent modification of histones.² Histones can be modified at various amino acid residues by acetylation, phosphorylation, methylation and ubiquitination³ and it has been suggested that particular combinations of these modifications constitute an “epigenetic code” for the regulation of gene expression.² Another prominent epigenetic modification is the methylation of cytosine residues in genomic DNA.⁴ About 4% of the cytosines are usually methylated in mammalian genomic DNA⁵ and it has been shown that this methylation is essential for mouse development.⁶ In addition, it has also been shown that DNA methylation plays an essential role in several epigenetic phenomena, including genomic imprinting,⁷ X-chromosome inactivation,⁸ and retroelement silencing.⁹

CpG dinucleotides represent the consensus target sequences of DNA methylation in differentiated mammalian cells, but only a relatively small fraction of these sequences becomes methylated.¹⁰ CpG dinucleotides can be clustered in CpG islands^{11,12} which are often associated with promoter regions and remain unmethylated for most genes. The signals that determine whether a particular CpG-containing sequence becomes methylated have not been determined yet, but it has been suggested that protein-protein interactions between DNA methyltransferases and chromatin-associated proteins might play an important role.¹³ As a consequence, DNA methylation is not evenly distributed over the genome. While the majority of repetitive elements are usually heavily methylated, gene-specific methylation appears to be rather restricted.

Genomic DNA methylation patterns can be drastically altered in human tumors.¹⁴ Due to the selective forces driving carcinogenesis, tumor cells are characterized by specific epigenetic changes that promote uncontrolled cellular proliferation.¹⁵ This explains the remarkable consistency of gene hypermethylation across all forms of human cancers.¹⁶ When hypermethylation affects the CpG islands of genes it can trigger their stable repression and thus has consequences that are functionally equivalent to genetic mutations.¹⁷ The acquisition of such an “epimutation” can therefore make an important contribution to cellular transformation. Over the past few years, the number of known epimutations has vastly increased. Prominent examples for genes “hit” by hypermethylation-induced silencing include the cell-cycle regulators *p15* and *p16*, the mismatch repair gene *MLH1*, as well as the apoptosis effector gene *Apaf-1*.¹⁸⁻²⁰ These epimutations constitute a tumor-specific epigenetic program that is reflected by the typical characteristics of human cancer cells, the lack of cell cycle control and aggressive growth.

DNA methylation is catalyzed by DNA methyltransferases, a family of enzymes that comprises DNMT1, DNMT2, DNMT3A and DNMT3B in human cells.²¹ To analyze the functional role of individual DNA methyltransferases in hypermethylation-induced gene silencing, homologous recombination has been used to disrupt DNMT1 and DNMT3B in the colorectal cancer cell line HCT116.^{22,23} Lack of DNMT1 or DNMT3B had little effect on the DNA methylation pattern. However, a double knockout cell line lacking both enzyme activities showed a very strong reduction in 5-methylcytosine content.²³ The effects of DNA methyltransferase knockouts on genomic DNA methylation patterns have been analyzed by two approaches:²⁴ Differential methylation hybridization, which detects methylated regions in the genome through a CpG island microarray, and amplification of inter-methylated sites, which amplifies anonymous DNA sequences with a differential methylation pattern. It was demonstrated that cells lacking both DNMT1 and DNMT3B undergo a substantial loss of DNA methylation in the promoter region of tumor suppressor genes.²⁴ This effect could not be seen in single DNMT knockout cell lines, and it was therefore concluded that different DNA methyltransferases cooperate in the epigenetic regulation of gene silencing.

DNA METHYLTRANSFERASE INHIBITORS AS DEMETHYLATING AGENTS

Based on the rationale that hypermethylation-induced gene silencing could be uncovered by gene demethylation and reactivation (Fig. 1), many laboratories have analyzed gene expression patterns in human cancer cells with experimentally reduced DNA methylation levels. To this end, DNA methyltransferase inhibitors,²⁵ like 5-azacytidine, 5-aza-2'-deoxycytidine and, to a lesser extent, zebularine, have found widespread use. All three compounds need to be metabolized and phosphorylated to deoxynucleotide triphosphates in order to become incorporated into DNA. DNA methyltransferases recognize the modified bases as natural substrate, but fail to resolve a covalent reaction intermediate,²⁶ which results in the degradation of the covalently trapped enzymes. DNA demethylation is a direct consequence of enzyme trapping because of ongoing DNA replication in the presence of diminished DNA methyltransferase levels. After several rounds of DNA replication, this becomes detectable as a substantial decrease in the genomic methylation level.

5-azacytidine is one of the best-known DNA methyltransferase inhibitors and has been used both in the laboratory and in the clinical practice for more than 20 years. The compound also represents the first established epigenetic drug, since it gained FDA approval for the treatment of myelodysplastic syndrome in May 2004. It was originally developed as a cytotoxic agent²⁷ and its demethylating activity was only discovered through its ability to influence cellular differentiation.²⁸ 5-azacytidine is a ribose nucleoside and thus needs to be metabolized into a deoxyribonucleoside-triphosphate before it can be incorporated into DNA. Indeed, a major fraction of the drug becomes incorporated into RNA and thereby interferes with protein biosynthesis.²⁹ This effect most likely plays a major role in the cytotoxicity of 5-azacytidine.

5-aza-2'-deoxycytidine is the deoxyribose analogue of 5-azacytidine and a promising new drug for the treatment of myelodysplastic syndrome and other leukemias. This compound is a more potent hypomethylating agent, but it does not become incorporated into RNA. However, high doses of 5-aza-2'-deoxycytidine still induce substantial cytotoxicity, which is attributable to various side




Figure 1. Establishment and reversion of epigenetic mutations. In healthy cells, tumor suppressor genes are unmethylated and expressed at normal levels. In cancer cells, hypermethylation of the promoter (and/or exon 1) region leads to gene silencing. Treatment with DNA methyltransferase inhibitors (DNMT inhibitors) removes the majority of 5-methylcytosine (CH₃), and can reactivate gene expression.

effects.³⁰ It was also shown that the differentiation inducing ability of decitabine in cultured fibroblasts had a narrow dose window, which provided a first indication that lower doses might induce demethylation with lower levels of overall cytotoxicity.²⁸ Both 5-azacytidine and 5-aza-2'-deoxycytidine are unstable in aqueous solutions,^{31,32} which has limited their clinical application.

The more recently discovered nucleoside inhibitor zebularine³³ is a stable cytidine analog that has shown promising characteristics in several *in vitro* assays as well as in mouse models.³⁴⁻³⁶ Cancer cell lines that responded to zebularine by DNA demethylation showed a complete depletion of the DNMT1 methyltransferase and a partial depletion of DNMT3A and DNMT3B.³⁶ Gene expression profiling revealed that zebularine specifically affected the gene expression patterns of human cancer cells, even if the number of genes upregulated by drug treatment was rather small (Table 1). Interestingly, zebularine was also shown to be active in mice when administered orally,³⁴ which suggested novel treatment modalities for epigenetic therapies. However, a recent study has demonstrated very low oral bioavailability in monkeys³⁷ and the clinical value of zebularine still remains to be determined.

IDENTIFICATION OF NOVEL TUMOR SUPPRESSOR GENES BY EXPERIMENTAL DEMETHYLATION

Because of the strong correlation between promoter hypermethylation and gene silencing, demethylating drugs have been repeatedly used for the identification of epigenetically silenced cancer genes. Transcriptional profiling in a variety of inhibitor-treated cancer cell lines revealed a relatively small number of genes that were significantly up or downregulated by demethylating drugs (Table 1). Two studies suggested that genes in the interferon pathway might be induced by 5-aza-2'-deoxycytidine treatment,^{38,39} but, otherwise, no defined gene expression signatures have been identified. Based on the rationale that tumor suppressor genes become hypermethylated and silenced

Table 1 Overview of gene expression changes induced by DNMT inhibitors

Cell Line	Drug	No. of Genes Analyzed	Genes Upreg. (%)	Genes Downreg. (%)	Reference
HT29	5-aza-CdR	4608	0.4	n.d.	38
T24	5-aza-CdR	6600	0.9	0.03	39
LD419	5-aza-CdR	6600	0.5	0.2	39
RKO	5-aza-CdR	10814	0.5	n.d.	41
KYSE30, KYSE410, KYSE520	5-aza-CdR	12599	1.0	n.d.	40
LNCAp	5-aza-CdR	1176	2.0	2.0	77
DU145	5-aza-CdR	1176	1.6	1.8	77
HCT116	5-aza-CdR	8000	0.8	0.6	43
HCT116 (1KO)	5-aza-CdR	8000	0.5	0.3	43
T24, HCT15, CFAPC-1	zebularine	13300	0.1	0.05	36
LD98, LD419, T-1, CCD-1070K	zebularine	13300	0.1	0.05	36
OCI-AML2	5-aza-CdR	22000	0.4	0.4	44

5-aza-CdR: 5-aza-2'-deoxycytidine; n.d., not determined




Figure 2. Clinical efficacy of DNA methyltransferase inhibitors in cancer patients. Survival of myelodysplastic syndrome patients treated with 5-azacytidine or supportive care, as determined by Kaplan-Meier analysis. Adapted from reference 48 with permission from the American Society of Clinical Oncology.

in cancer cells, pharmacological inhibition of DNA methyltransferases was also used to uncover novel cancer-related genes. Transcriptional profiling of esophageal squamous cell carcinoma (ESCC) cell lines treated with 5-aza-2'-deoxycytidine identified ten putative tumor suppressor genes that were found to be methylated in primary tumor tissues.⁴⁰ Three of these genes, *CRIP-1*, *Apo D* and *NU* were over-expressed in ESCC cells and found to strongly inhibit their ability to grow colonies.⁴⁰ This provided an indication that all three genes might function as suppressors of tumor growth. In a similar study, the genes encoding *secreted frizzled-related proteins* (*SFRPs*) were identified through a genomic screen for genes upregulated by

demethylation and were subsequently found to be hypermethylated in colorectal cancers.⁴¹ More recently, it has been shown that epigenetic silencing of *SFRP* genes plays a functional role in the constitutive activation of the WNT signalling pathway, which further underscored the significance of these events for colorectal carcinogenesis.⁴²

To compare the effects of pharmacological and genetic inactivation of DNA methyltransferases, transcriptional profiles of knockout cells were compared to those obtained from inhibitor-treated cells.⁴³ Interestingly, the effects of 5-aza-2'-deoxycytidine appeared fully established after 24 hours and more closely resembled those of histone deacetylase inhibitor (TSA) treatment than the effects of DNA methyltransferase knockouts. These results cannot be explained by the covalent trapping of DNA methyltransferases, followed by passive demethylation of DNA. Rather, it seems likely that active demethylation is triggered by the pharmacological inhibitors through an

upstream mechanism involved in the regulation of both DNA methylation and histone deacetylation. Another surprising finding was the substantial fraction of genes found to be downregulated after exposure to 5-aza-2'-deoxycytidine. In contrast to the prevailing view, this suggested that hypomethylation may also be associated with gene silencing. Consistently, demethylation of the APM2 promoter region closely coincided with its transcriptional silencing.⁴³

The validity of the results obtained with cell lines was confirmed by a study that used primary cells from leukemia patients after treatment with 5-aza-2'-deoxycytidine ex vivo or in vivo.⁴⁴ The transcriptional profiles obtained in these experiments were comparable to those obtained in cultured cell lines, which suggested that the molecular responses in cells and in patients might be similar. However, only half of the induced genes contained putative CpG islands in their 5' promoter region and only a fraction of those showed changes in their methylation patterns. This result provides a good starting point for a review of the complex data on drug-induced methylation changes in patient material.

THE USE OF DEMETHYLATING DRUGS IN CLINICAL TRIALS

Both 5-azacytidine and 5-aza-2'-deoxycytidine have been used in dozens of clinical trials for more than 20 years.^{45,46} In agreement with standard procedures, most early trials used the drugs at concentrations that were close to the maximum tolerated dose. The clinical results were generally disappointing and included severe toxicities related to prolonged myelosuppression. More recently, treatment schedules have been adjusted to increase drug tolerance,⁴⁷ which has allowed the completion of several effective low-dose trials and provided the foundation for an increased clinical interest in DNA methyltransferase inhibitors. A randomized, controlled phase III trial of low-dose 5-azacytidine vs. supportive care in myelodysplastic syndrome patients⁴⁸ showed a significant clinical benefit in

drug-treated patients (Fig. 2). Similar results appear to have been obtained in a phase III clinical trial of 5-aza-2'-deoxycytidine.⁴⁹ In addition, promising clinical responses have also been reported in phase I trials of low-dose 5-aza-2'-deoxycytidine in other leukemias, including AML and CML.^{50,51} These results suggest that the demethylation induced by azanucleoside drugs might be of general benefit for the reversion of epigenetic lesions in cancer patients.

Drug-induced methylation changes have only recently been analyzed in the clinical setting. One of the first such studies focused on the methylation of the p15 tumor suppressor gene in the bone marrow of 5-aza-2'-deoxycytidine-treated patients with myelodysplastic syndrome.⁵² The results suggested demethylation in nine out of 12 patients and also provided evidence of p15 reactivation by immunohistochemistry in four patients. It remains a possibility that these changes are at least partially attributable to the expansion of nonclonal cells in responding patients, but gene reactivation was also shown in morphologically dysplastic cells from patients that were not in complete remission. This indicated a significant potential of the drug to activate gene expression in tumors and also suggested a direct involvement of DNA demethylation.⁵² However, there appeared to be no correlation between p15 demethylation and clinical response to decitabine in a larger phase I study of decitabine in MDS and AML patients.⁵⁰ Overall similar results were also obtained in a phase I study of 5-azacytidine in Epstein-Barr virus-associated tumors.⁵³ While these tumors showed substantial demethylation in the EBV promoter, reactivation of EBV expression could only be observed in one case and there appeared to be no detectable clinical response.

Biological responses might be maximized by changes in the drug delivery schedule, and for this reason different schedules are currently being tested. In some of these clinical trials, the clinical responses are being analyzed in parallel with the changes in genomic DNA methylation patterns (Fig. 3). One such example is provided by a recent phase I study of continuous 5-aza-2'-deoxycytidine infusion in a small group of patients with refractory solid tumors.⁵⁴ While the patient group was too small to assess the clinical benefit of the treatment schedule, all patients showed indications for demethylation in blood samples. This effect could be observed either by quantitative PCR-based methylation analysis of the MAGE-1 promoter or by HPLC analysis of genomic DNA. Importantly, it could also be shown that DNA methylation reverted to pretreatment levels within four weeks, which indicated that drug-induced demethylation is transient. These findings are in agreement with an analysis of drug-induced demethylation effects observed after 5-aza-2'-deoxycytidine treatment of MDS patients.⁵⁵ Here, the analysis of global DNA methylation levels from serial bone marrow samples indicated strong demethylation after the fourth treatment cycle, while karyotype normalization had occurred after the second treatment cycle. This indicated an important role of drug-mediated cytotoxicity, followed by a substantial demethylation of nonclonal cells. Again, DNA










Figure 3. Epigenetic cancer therapy. After diagnosis, cancer patients can be treated with DNA methyltransferase and/or histone deacetylase inhibitors. Treatment response is being monitored at clinical and molecular levels by analysis of tumor and peripheral blood samples. Correlations between clinical and molecular parameters will be important for the optimization of clinical treatment schedules.

methylation returned to pretreatment levels several weeks after the last treatment cycle, which confirmed the transient nature of the demethylating effect.

The dynamics of drug-induced demethylation will be important for the design of combination trials that address the potential synergy between demethylating drugs and other chemotherapeutic agents. Experiments with mouse xenograft tumors have shown a strong chemosensitizing effect for 5-aza-2'-deoxycytidine when the drug was administered a few days before standard cytotoxic drugs.⁵⁶ This effect is presumably due to the epigenetic reactivation of apoptosis effector and DNA repair genes. 5-aza-2'-deoxycytidine has also been shown to be effective in a clinical combination study with the tyrosine kinase inhibitor imatinib mesylate (Gleevec).⁵¹ A complete hematological response after decitabine treatment was seen in up to 50% of the Gleevec-resistant patients in the chronic phase of the disease. Furthermore, the demethylating effect was assessed by methylation analysis of LINE-1 elements as well as p15 tumor suppressor gene. Surprisingly, the degree of LINE-1 hypomethylation at the end of therapy was higher in patients who did not subsequently respond to therapy. This has been interpreted to reflect the possibility that hypomethylated cells die more rapidly, while cells resistant to therapy can withstand higher degrees of hypomethylation.⁵¹

Lastly, it will also be critical to design treatment schedules that maximize the reversion of epigenetic mutations with minimal influences on epigenetic effects required for normal cellular functions.⁵⁷ This is an important aspect in light of the finding that strong and continuous demethylation in animal and cellular models have been shown to promote genome instability and thereby induce tumor formation.^{58,59} A recent analysis used *Apc^{min}* mice with three different levels of the DNA maintenance methyltransferase DNMT1 to model the degree of hypomethylation observed in tumors (Yamada intestinal tumorigenesis but promotes microadenoma formation in

Table 2 Overview of DNA methyltransferase inhibitors

Compound	Proposed Inhibitory Mechanism	Structure
<i>azanucleoside derivatives</i>		
5-azacytidine (Vidaza) 5-aza-2'-deoxycytidine (Decitabine, Dacogen)	Covalent enzyme trapping (26)	
zebularine	Covalent enzyme trapping (33)	
<i>small-molecule compounds</i>		
hydralazine	noncovalent enzyme inhibition (68)	
procaine (procainamide)	binding to CpG-rich DNA (65), competitive inhibition of DNMT1 (66)	
(-)-epigallocatechin-3-gallate (EGCG)	noncovalent enzyme inhibition (70)	
RG108	noncovalent enzyme inhibition (73)	

determined, it suggests that epigenetic therapies could benefit from a further refinement of treatment schedules and the use of more specific drugs.

DEVELOPMENT OF NOVEL DNA METHYLTRANSFERASE INHIBITORS

The apparent lack of specificity and the inherent toxicity of nucleoside inhibitors have invigorated the search for alternative DNA methyltransferase inhibitors.²⁵ The aim has been to identify compounds that do not need to be incorporated into DNA and thus would circumvent the toxic side-effects caused by the formation of protein-DNA adducts.⁶¹ Alternatively, it might also be feasible to reduce DNA methyltransferase activity through oligonucleotides, either by allosteric enzyme inhibition⁶² or by siRNA-mediated mRNA degradation.^{63,64}

There are several small-molecule-like compounds that have been described to induce demethylation in human cancer cell lines (Table 2). Interestingly, some of these represent established drugs for the treatment of diseases not related to cancer. For example, the local anaesthetic procaine and its derivative procainamide, an approved antiarrhythmic drug, have been described to cause significant demethylation of genomic DNA in human cancer cell lines.^{65,66} This was confirmed by drug-induced demethylation and reactivation of the hypermethylated RAR β 2 tumor suppressor gene.⁶⁵ To explain the demethylating effects, it was suggested that procaine and procainamide associate with CpG-rich sequences in the genome and thereby interfere with the DNA methylation machinery.⁶⁵ Additionally, it has also been suggested that procainamide decreases the affinity of DNMT1 for both DNA and the methyl-group donor S-adenosyl-L-methionine.⁶⁶

In this context, demethylation of centromeric satellite elements might play an important role in chromosomal instability.¹⁴ The analysis of DNA from decitabine-treated MDS patients after various treatment time points demonstrated that drug-induced hypomethylation also led to demethylation of chromosome 1 satellite 2 sequences,⁵⁵ which has been linked to chromosomal instability.⁶⁰ While the clinical significance of this observation remains to be

Inhibition of DNA methylation has also been reported for hydralazine, an established antihypertensive drug that has been described to have demethylating activity in human cancer cell lines.⁶⁷ Experimental results derived from gene-specific and whole-genome methylation analyses suggested significant drug-induced demethylation that was accompanied by corresponding gene reactivation.^{67,68} Results from a recent phase I of hydralazine in

cervical cancer patients also indicated demethylation and concomitant reactivation of hypermethylated tumor suppressor genes in tumor samples.⁶⁸ While these results seemed impressive at first, it needs to be pointed out that a recent cross-comparison of DNA methyltransferase inhibitors failed to reveal any significant activity for procainamide and hydralazine.⁶⁹

For two additional compounds, experimental evidence has been provided that suggests a direct inactivation of DNA methyltransferases. The first example is provided by (-)-epigallocatechin-3-gallate (EGCG), the primary phenolic component of green tea. EGCG inhibited DNA methyltransferase activity in protein extracts derived from human cancer cell lines and also caused demethylation and reactivation of epigenetically silenced tumor suppressor genes. Treatment of cancer cells with EGCG led to a reduction of DNA methylation that is paralleled by a reactivation of formerly hypermethylated tumor suppressor genes.⁷⁰ However, the drug is also known to be a strong oxidizing agent⁷¹ and it appears possible that the observed effects on DNA methylation might be an indirect consequence of oxidative reactions. The second example for a DNA methyltransferase inhibitor with a direct inhibitory mechanism is RG108, a small molecule identified in an *in silico* screen with an active site model of the human DNMT1 enzyme.⁷² RG108 represents the first compound that shows methyltransferase inhibiting activity both in a well-defined cell-free assay and in human cancer cell lines.⁷³ In addition, RG108 showed very little toxicity, but increased specificity for hypermethylated tumor suppressor genes. The substantial hydrophobicity of RG108 currently represents an important restriction to its more widespread application. However, its easily optimizable structure provides an excellent opportunity for the generation of improved derivatives.

There are several strategies that can now be used for the identification of novel, more specific and potentially more active inhibitors. Computational methods are becoming increasingly important for rational drug design and it seems plausible to perform more expanded *in silico* screens using homology models of human DNA methyltransferase enzymes.⁷⁴ A similar approach has resulted in the identification of RG108^{72,73} and could be further refined as soon as the major human enzymes, DNMT1, DNMT3A and DNMT3B have been crystallized and their structural conformations have been determined. Recent developments also indicate the possibility of establishing high-throughput screening platforms for the identification of novel DNA methyltransferase inhibitors. For example, it has been shown that the inhibition of DNA methyltransferase activity can be visualized on ELISA plates by immunological methods.⁷⁵ In this assay, one strand of the template DNA was digoxigenin-labelled at the 3'-end while the 3'-end of the complementary strand was tagged with biotin and immobilized on streptavidin coated plates. After completion of the methylation reaction in the presence or absence of inhibitory compounds, the methylation status of the template DNA was probed by a methylation-sensitive restriction enzyme. The extent of methylation inhibition was quantified using standard ELISA procedures after immunodetection of digoxigenin. Lastly, it might now also be feasible to identify and characterize new inhibitors more directly in cell-based assays. It has recently been shown that the covalent trapping of GFP-labelled DNMT1 by 5-azacytosine can be visualized and quantified through fluorescence recovery after photobleaching.⁷⁶ By extension, it has been suggested that direct inhibitors of DNMT1 would compete with the covalent enzyme trapping induced by 5-azacytosine and thereby cause a quantifiable increase in the amount of free GFP-tagged protein.

While the general feasibility of this approach remains to be determined, it is likely that defined cell-based assays represent an important tool for the rational development of DNA methyltransferase inhibitors.

References

- Li E. Chromatin modification and epigenetic reprogramming in mammalian development. *Nat Rev Genet* 2002; 3:662-73.
- Jenuwein T, Allis CD. Translating the histone code. *Science* 2001; 293:1074-80.
- Turner BM. Reading signals on the nucleosome with a new nomenclature for modified histones. *Nat Struct Mol Biol* 2005; 12:110-2.
- Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev* 2002; 16:6-21.
- Gama-Sosa MA, Midgett RM, Slagel VA, Githens S, Kuo KC, Gehrke CW, Ehrlich M. Tissue-specific differences in DNA methylation in various mammals. *Biochim Biophys Acta* 1983; 740:212-9.
- Li E, Bestor TH, Jaenisch R. Targeted mutation of the *DNA* methyltransferase gene results in embryonic lethality. *Cell* 1992; 69:915-26.
- Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. *Nature* 1993; 366:362-5.
- Panning B, Jaenisch R. DNA hypomethylation can activate *Xist* expression and silence *X-linked* genes. *Genes Dev* 1996; 10:1991-2002.
- Walsh CP, Chaillet JR, Bestor TH. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. *Nat Genet* 1998; 20:116-7.
- Ramsahoye BH, Biniszkiwicz D, Lyko F, Clark V, Bird AP, Jaenisch R. NonCpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. *Proc Natl Acad Sci USA* 2000; 97:5237-42.
- Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. *J Mol Biol* 1987; 196:261-82.
- Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. *Proc Natl Acad Sci USA* 2002; 99:3740-5.
- Burgers WA, Fuks F, Kouzarides T. DNA methyltransferases get connected to chromatin. *Trends Genet* 2002; 18:275-7.
- Ehrlich M. DNA methylation in cancer: Too much, but also too little. *Oncogene* 2002; 21:5400-13.
- Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 2002; 3:415-28.
- Esteller M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. *Oncogene* 2002; 21:5427-40.
- Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. *Trends Genet* 2000; 16:168-74.
- Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. *Cancer Res* 1997; 57:837-41.
- Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci USA* 1998; 95:6870-5.
- Soengas MS, Capodiceci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. *Nature* 2001; 409:207-11.
- Grace Goll M, Bestor TH. Eukaryotic cytosine methyltransferases. *Annu Rev Biochem* 2005; 74:481-514.
- Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained in human cancer cells lacking DNMT1. *Nature* 2000; 404:1003-7.
- Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. *DNMT1* and *DNMT3b* cooperate to silence genes in human cancer cells. *Nature* 2002; 416:552-6.
- Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. *Cancer Res* 2003; 63:1114-21.
- Brueckner B, Lyko F. DNA methyltransferase inhibitors: Old and new drugs for an epigenetic cancer therapy. *Trends Pharmacol Sci* 2004; 25:551-4.
- Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. *Proc Natl Acad Sci USA* 1984; 81:6993-7.
- Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. *Experientia* 1964; 20:202-3.
- Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 1980; 20:85-93.
- Cihak A. Biological effects of 5-azacytidine in eukaryotes. *Oncology* 1974; 30:405-22.
- Mompalmer RL, Mompalmer LF, Samson J. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. *Leuk Res* 1984; 8:1043-19.
- Notari RE, DeYoung JL. Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions. *J Pharm Sci* 1975; 64:1148-57.
- Lin KT, Mompalmer RL, Rivard GE. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. *J Pharm Sci* 1981; 70:1228-32.

33. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. *J Mol Biol* 2002; 321:591-9.
34. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. *J Natl Cancer Inst* 2003; 95:399-409.
35. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. *Mol Cell Biol* 2004; 24:1270-8.
36. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA. Preferential response of cancer cells to zebularine. *Cancer Cell* 2004; 6:151-8.
37. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio DZ, Egorin MJ. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. *Clin Cancer Res* 2005; 11:3862-8.
38. Karpf AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H, Jones DA. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. *Proc Natl Acad Sci USA* 1999; 96:14007-12.
39. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. *Cancer Res* 2002; 62:961-6.
40. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. *Cancer Cell* 2002; 2:485-95.
41. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. *Nat Genet* 2002; 31:141-9.
42. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Dong Chen W, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB. Epigenetic inactivation of *SFRP* genes allows constitutive WNT signaling in colorectal cancer. *Nat Genet* 2004; 36:417-22.
43. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, Young L, Brandenburg SA, Hu Y, Bishr KS, Ho AS, Mattson D, Sun L, Munson PJ, Chuang EY, Mitchell JB, Feinberg AP. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. *Cancer Cell* 2004; 6:361-71.
44. Schmelz K, Sattler N, Wagner M, Lübbert M, Dörken B, Tamm I. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (*AML*) and myelodysplastic syndrome (*MDS*) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. *Leukemia* 2005; 19:103-11.
45. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. *Curr Top Microbiol Immunol* 2000; 249:135-64.
46. Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. *Curr Opin Investig Drugs* 2002; 3:627-33.
47. Kantarjian HM, Issa JP. Decitabine dosing schedules. *Semin Hematol* 2005; 42:S17-22.
48. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. *J Clin Oncol* 2002; 20:2429-40.
49. Saba HI, Wijermans PW. Decitabine in myelodysplastic syndromes. *Semin Hematol* 2005; 42:S23-31.
50. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood* 2004; 103:1635-40.
51. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to Imatinib mesylate. *J Clin Oncol* 2005; In press.
52. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lübbert M. Demethylation of a hypermethylated *P15/INK4B* gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. *Blood* 2002; 100:2957-64.
53. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW, Johnson PJ, Ambinder RF. Azacitidine induces demethylation of the *Epstein-Barr* virus genome in tumors. *J Clin Oncol* 2004; 22:1373-81.
54. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. Evaluation of a 7-Day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation. *J Clin Oncol* 2005; In press.
55. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2'-deoxycytidine in patients with myelodysplastic syndrome. *Cancer Res* 2005; In press.
56. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the *hMLH1* gene promoter. *Cancer Res* 2000; 60:6039-44.
57. Lyko F, Brown R. DNA methyltransferase inhibitors and the establishment of epigenetic cancer therapies. *J Natl Cancer Inst* 2005; 97:1498-506.
58. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. Induction of tumors in mice by genomic hypomethylation. *Science* 2003; 300:489-92.
59. Karpf AR, Matsui S. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. *Cancer Res* 2005; 65:8635-9.
60. Widschwendter M, Jiang G, Woods C, Muller HM, Fiegl H, Goebel G, Marth C, Muller-Holzner E, Zeimet AG, Laird PW, Ehrlich M. DNA hypomethylation and ovarian cancer biology. *Cancer Res* 2004; 64:4472-80.
61. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. *Proc Natl Acad Sci USA* 1994; 91:11797-801.
62. Flynn J, Fang JY, Mikovits JA, Reich NO. A potent cell-active allosteric inhibitor of murine DNA cytosine C5 methyltransferase. *J Biol Chem* 2003; 278:8238-43.
63. Milutinovic S, Knox JD, Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor *p21(WAF1/CIP1/sdi1)*. *J Biol Chem* 2000; 275:6353-9.
64. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. DNMT1 is required to maintain *CpG* methylation and aberrant gene silencing in human cancer cells. *Nat Genet* 2003; 33:61-5.
65. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. *Cancer Res* 2003; 63:4984-9.
66. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. *J Biol Chem* 2005; In press.
67. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A, Acuna C, Salazar AM, Lizano M, Duenas-Gonzalez A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. *Clin Cancer Res* 2003; 9:1596-603.
68. Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Duenas-Gonzalez A. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. *BMC Cancer* 2005; 5:44.
69. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, Jones PA. Comparison of biological effects of nonnucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. *Mol Cancer Ther* 2005; 4:1515-20.
70. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res* 2003; 63:7563-70.
71. Elbling L, Weiss RM, Teufelhofer O, Uhl M, Knasmueller S, Schulte-Hermann R, Berger W, Micksche M. Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. *Free Radic Biol Med* 2005; 19:807-9.
72. Siedlecki P, Boy RG, Musch T, Brueckner B, Suhai S, Lyko F, Zielenkiewicz P. Discovery of two novel small-molecule inhibitors of DNA methylation. *J Med Chem* 2006; In press.
73. Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M, Lyko F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. *Cancer Res* 2005; 65:6305-11.
74. Siedlecki P, Boy RG, Comagic S, Schirmacher R, Wiessler M, Zielenkiewicz P, Suhai S, Lyko F. Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. *Biochem Biophys Res Commun* 2003; 306:558-63.
75. Woo YH, Rajagopalan PT, Benkovic SJ. A nonradioactive DNA methyltransferase assay adaptable to high-throughput screening. *Anal Biochem* 2005; 340:336-40.
76. Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC, Leonhardt H. Trapped in action: Direct visualization of DNA methyltransferase activity in living cells. *Nat Methods* 2005; 2:751-6.
77. Yamada Y, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Takagi A, Matsuzaki T, Sugimura Y, Yatani R, Shiraishi T. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer. *Cancer Sci* 2003; 94:536-9.
78. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, Jaenisch R. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. *Proc Natl Acad Sci USA* 2005; 102:13580-5.